Which antibiotics increase risk of sudden death in your patient on haemodialysis? Probably something you should know. Check out our rapid-fire summary tweetorial at the link!
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
Which antibiotics increase risk of sudden death in your patient on haemodialysis? Probably something you should know. Check out our rapid-fire summary tweetorial at the link!
⚖️As doctors we guide our practice by the principle: primum, non nocere
— Nephrology Jrnl Club (@NephJC) July 22, 2022
⁉️ Premise: pt on hemodialysis develops pneumonia. What antibiotic would you use?
Welcome to #TenTweetNephJC
✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/PHeR0c7EkV